EMBRACE - Early detection of Brain Cancer using a novel spectroscopic liquid biopsy enabling timely detection and diagnosis for patient benefit

拥抱 - 使用新型光谱液体活检早期检测脑癌，能够及时检测和诊断，造福患者

• 批准号: 10066539
• 金额: $ 269.77万
• 依托单位: DXCOVER LIMITED
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10066539
• 关键词: EMBRACE; Early; detection; Brain; Cancer

Dxcover is a clinical stage diagnostics company, dedicated to delivering innovative early cancer diagnostics to the clinic. Using our platform technology, we will provide the world’s first game-changing blood test for brain cancer detection (Dxcover Brain) that fits seamlessly into current standard-of-care pathway. Brain cancer reduces life expectancy by over 20 years on average, a statistic that is largely attributed to its late detection. The diagnostic pathway is highly inefficient, as currently only ~2% of patients referred for imaging actually have brain cancer. Dxcover’s unique technology uses infrared light to detect signals from the tumour and signals from the body’s response to the tumour. Currently validated in >3000 patient samples across multiple clinical studies, we provides a simple workflow, and a fast and affordable solution for early cancer detection. EIC funding will allow Dxcover to obtain CE-IVDR approval, target the European market and reach the patient faster.

Dxcover是一家临床阶段诊断公司，致力于为临床提供创新的早期癌症诊断。利用我们的平台技术，我们将提供世界上第一个改变游戏规则的脑癌检测血液测试（Dxcover brain），无缝地符合当前的标准护理途径。脑癌使预期寿命平均缩短了20多年，这一统计数据在很大程度上归因于它的发现较晚。诊断途径效率非常低，因为目前只有约2%的患者接受影像学检查确实患有脑癌。Dxcover的独特技术使用红外光来检测来自肿瘤的信号和身体对肿瘤的反应信号。目前，我们在多个临床研究中验证了超过3000例患者样本，为早期癌症检测提供了简单的工作流程和快速且经济实惠的解决方案。EIC资金将使Dxcover获得CE-IVDR批准，瞄准欧洲市场并更快地到达患者手中。